LONGEVA.

GHK-Cu: limits of adverse-event evidence

Maquart and colleagues studied the GHK-Cu copper complex in fibroblast cultures, measuring collagen synthesis. The inspected abstract of this 1988 study gives no clinical adverse-event frequencies. [1]

A cell experiment cannot establish adverse reactions or safety of GHK-Cu administration in humans. It also does not establish risks for a particular reagent batch or a blend with other compounds. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Clinical adverse eventsFibroblast cultures (cell experiment measuring collagen synthesis)The abstract gives no clinical adverse-event frequencies; a cell experiment cannot establish adverse reactions or safety of administration in humans[1]

References

  1. Maquart FX et al. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ https://doi.org/10.1016/0014-5793(88)80509-X.